STOCK TITAN
  1. Home
  2. News
  3. ABVC

ABVC BioPharma, Inc. - ABVC STOCK NEWS

Welcome to our dedicated page for ABVC BioPharma news (Ticker: ABVC), a resource for investors and traders seeking the latest updates and insights on ABVC BioPharma stock.

ABVC BioPharma, Inc. (NASDAQ: ABVC) is a clinical-stage biopharmaceutical company dedicated to developing therapeutic solutions in the fields of oncology/hematology, central nervous systems (CNS), and ophthalmology. Founded in 2015 and headquartered in Fremont, California, the company is focused on addressing unmet medical needs through its pipeline of innovative drugs and medical devices.

ABVC BioPharma, along with its subsidiaries like BioLite, Inc. and BioFirst Corporation, has an active pipeline comprising six drugs and one medical device (ABV-1701/Vitargus®) under development. ABVC harnesses licensed technology from renowned research institutions such as Stanford University, the University of California at San Francisco, and Cedars-Sinai Medical Center to conduct proof-of-concept trials up to Phase II of clinical development. The company’s flagship product, Vitargus®, is a groundbreaking vitreous substitute for retinal detachment surgery and is currently undergoing global clinical trials.

The company’s drug candidates include:

  • ABV-1501 – A combination therapy for triple-negative breast cancer.
  • ABV-1504 – Designed for treating major depressive disorder (MDD).
  • ABV-1505 – Targets attention deficit hyperactivity disorder (ADHD).
  • ABV-1702 – For the treatment of myelodysplastic syndromes (MDS).
  • ABV-1703 – Focused on the treatment of pancreatic cancer.
  • ABV-1601 – Aimed at treating depression in cancer patients.

ABVC has entered several strategic partnerships and licensing agreements to advance its pipeline. These include co-development agreements with Rgene Corporation and BiohopeKing Corporation for ABV-1501, and collaborative efforts with BioFirst Corporation for the co-development of BFC-1401 vitreous substitute for vitrectomy and ABV-1701 Vitargus for retinal detachment or vitreous hemorrhage.

Recent achievements include a global licensing agreement with AiBtl BioPharma Inc. for CNS drugs targeting MDD and ADHD, valued at $667 million, and the acquisition of a U.S. patent for the use of PDC-1421 (Polygala extract) in treating ADHD. ABVC is also involved in strategic investments such as the acquisition of real estate in Taoyuan City, Taiwan, to develop plant factories for its botanical drug pipeline.

ABVC BioPharma is committed to bringing high-efficacy, low-toxicity botanically based solutions to the market, improving health outcomes for patients worldwide. The company’s focus on strategic partnerships, innovative research, and global clinical trials positions it as a significant player in the biopharmaceutical industry.

News

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

Rhea-AI Summary
ABVC BioPharma, Inc. CEO Dr. Uttam Patil recognized as a Top 10 CEO in Taiwan 2024 for his exceptional leadership and contributions. The Company has seen a rise in stock price, international growth, and success under his guidance. Dr. Patil's focus on innovation, sustainable practices, and community engagement reflects his commitment to excellence and long-term shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
none
-
News

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

Rhea-AI Summary
ABVC BioPharma, Inc. announces 2023 financial results, strategic investments, licensing deals, and operational highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
earnings
-
News

ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars

Rhea-AI Summary
ABVC BioPharma, Inc. provides an update on the development of combination therapy for cancer and immunity booster dietary supplements derived from Maitake Mushroom. The company is marketing supplements and pursuing clinical trials of pharmaceutical compounds approved by the US FDA. BioKey, the company's subsidiary, is working on the manufacturing and distribution of these products, aiming to tap into the growing global markets for cancer therapeutics, dietary supplements, and pharmaceutical CDMO services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
News

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) signs a definitive agreement to license its healthcare-related expertise to Senior Paradise, Inc. for further development in the healthcare industry. The agreement includes leasing the Company's properties for projects such as a long-term care center and plant factories. SPI will pay ABVC $3M as a license fee and 2% royalties on revenues. The strategic partnership aims to maximize the value of ABVC's resources and potentially create a new revenue stream.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
none
-
News

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) secures Australian patent for PDC-1421 extract for Major Depressive Disorder treatment until 2040. The Company's asset ABV-1504, a botanical-based NET inhibitor, completes Phase II studies for MDD. ABVC enters global licensing agreement with AiBtl BioPharma Inc. for CNS drugs, expecting significant revenue potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
News

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

Rhea-AI Summary
ABVC BioPharma, Inc. has signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan, estimated at approximately $2.96 million. The acquisition aims to develop plant factories for ABVC’s botanical pipeline and establish a base for Good Agricultural Practices fields. The company will issue shares of common stock and a warrant to purchase up to 1,000,000 shares of common stock in consideration for ownership of the property. The acquisition is expected to raise shareholders' equity and facilitate ABVC’s drug development plan, generating future revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
acquisition
News

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) and its subsidiary BioLite, Inc. announced that they received 46 million shares from AiBtl BioPharma Inc. as the first milestone payment under a global licensing agreement. The agreement values the payment at $460. The Company's pipeline of products has excellent market potential, with the MDD market expected to reach $14.96 billion by 2032 and the global ADHD treatment market expected to grow at a CAGR of 7.3% between 2023-2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
60.83%
Tags
none
-
News

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) provided an update on the eight-week long ADHD Phase II part II clinical study at the University of California San Francisco Medical Center and five Taiwanese medical centers. Out of 94 screened subjects, 69 enrolled, and 60 completed the study. The Phase II part I clinical study successfully achieved primary endpoints and was accepted by the FDA. The CEO expects positive results in the interim analysis report and plans to continue the study by enrolling another thirty patients. The global ADHD treatment market is projected to reach $32.14 billion by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.41%
Tags
clinical trial
-
News

ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials

Rhea-AI Summary
ABVC BioPharma, Inc. (ABVC) shared an interview with Dr. Scott Irwin, MD, Ph.D., the Principal Investigator for the clinical trials of ABV-1601, the Company’s drug under development to treat depression in cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
clinical trial
News

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

Rhea-AI Summary
ABVC BioPharma, Inc. (ABVC) announced the receipt of a U.S. patent for PDC-1421, a Radix Polygala extract used in their asset ABV-1505 targeting ADHD. The patent grants exclusivity until 2040. ABVC is awaiting patent applications in the EU, China, and Japan. ABV-1505, a botanical-based NET inhibitor, is in Phase IIb clinical studies for ADHD treatment. The global ADHD treatment market is projected to reach $32.14 billion by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
none

FAQ

What is the current stock price of ABVC BioPharma (ABVC)?

The current stock price of ABVC BioPharma (ABVC) is $0.51 as of December 24, 2024.

What is the market cap of ABVC BioPharma (ABVC)?

The market cap of ABVC BioPharma (ABVC) is approximately 6.2M.

What does ABVC BioPharma, Inc. specialize in?

ABVC BioPharma specializes in developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology.

Where is ABVC BioPharma, Inc. headquartered?

ABVC BioPharma is headquartered in Fremont, California.

What are the key products in ABVC BioPharma’s pipeline?

Key products include ABV-1501 for triple-negative breast cancer, ABV-1504 for major depressive disorder, ABV-1505 for ADHD, ABV-1702 for MDS, ABV-1703 for pancreatic cancer, and ABV-1601 for depression in cancer patients.

What recent partnerships has ABVC BioPharma formed?

Recent partnerships include a global licensing agreement with AiBtl BioPharma Inc. for CNS drugs targeting MDD and ADHD, and a co-development agreement with Rgene Corporation and BiohopeKing Corporation for ABV-1501.

What is ABVC BioPharma’s flagship product?

ABVC BioPharma’s flagship product is Vitargus®, a vitreous substitute for retinal detachment surgery.

What recent achievements has ABVC BioPharma made?

Recent achievements include acquiring a U.S. patent for PDC-1421 for ADHD treatment and the acquisition of real estate in Taiwan for developing plant factories.

What is the focus of ABVC BioPharma’s research?

ABVC BioPharma focuses on developing botanically based solutions with high efficacy and low toxicity to improve health outcomes.

Who are some of ABVC BioPharma’s research partners?

Research partners include Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center.

How does ABVC BioPharma aim to improve patient outcomes?

ABVC BioPharma aims to improve patient outcomes through innovative, high-efficacy, low-toxicity botanically based solutions.

What can investors expect from ABVC BioPharma in the future?

Investors can expect continued innovation, strategic partnerships, and the global advancement of ABVC BioPharma’s therapeutic solutions.

Stock ABVC logo
ABVC BioPharma, Inc.

Nasdaq:ABVC

ABVC Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ABVC Stock Data

6.24M
10.13M
22.93%
3.01%
1.5%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FREMONT